| Reference: | Chien, Bih, Chou, Lin, Lee, and Chou (2007), “Trends in the use of psychotropic drugs in Taiwan：A Population-Based National Health Insurance Study,1997-2004”, Psychiatric services ,vol.58 No.4.
Chou (2003) , “Patterns and costs of antipsychotic drug use in Taiwan：1997 to 2001”,
Advances in Therapy, 20(6), 344-351.
Duggan, M. (2005), “ Do new prescription drugs pay for themselves? The case of second-generation antipsychotics”, Journal of Health Economics, 24, 1-31.
Frank, R. G., McGuire. T. G., Normand. S. L. (2006), “Cost-offsets of new mdications for treatment of schizophrena” ,National bureau of economic reseatch ,working paper 12643.
Henderson, D. C., Cargliero, E., Gray, C., et.al. (2000), “Clozapine, diabetes mellitus, weight gain, and lipid abnormalities a five-yearnaturalistic study.”, Am J Psychiatry ,157, 975-981.
Johantgen, M. E., Coffey, R. M., Harris, D. R., Levy, H., Clinton, J. J. (1995), “Treating early-stage breast cancer：hospital characteristics associated with surgery.”, American Journal of Public Health, 85, 1432-4.
Lichtenberg, F. R. (2002), “Benefits and costs of newer drugs：an update”, National bureau of economic research, working paper 8996.
Rosenheck, R., Perlick, D., Bingham, S. et.al. (2003), “Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophreniz：A Randomized Cotrolled Trial.”, Journal of the American Medical Association, 290, 2693-2702.
Sebastian, C. S., Glazer, W., Buckley, P.F. (2004), “Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia”, Current Medical Chemisty , 11,329-342.
Sernyak, M. J., Leslie, D. L., Alarcon, R. D., et.al. (2002), “Association of diabetes mellitus with useof atypical neuroleptics in the treatment of schizophrenia.”, Am J Psychiatry, 159, 561-566.
Wolf, B., Grohmmann, R., Schmidt, L.G., Ruther, E. (1989), “Psychiatric admissions due to adverse drug reactions”, Comrehensive Psychiatry, 534-45.
張明永 (2001),《全民健保精神分裂症住院病患精神科藥品使用狀態及其經濟效益評估》,行政院衛生署90年度委託研究計畫,計畫編號DOH90-NH-010。
張明永 (2003),《全民健康保險精神分裂症病患用藥型態分析》,行政院衛生署92年度委託研究計畫, 計畫編號DOH92-NH-1025。
高純琇 (2004),《全民健保精神疾病住院歸人檔縱貫性藥物流行病學研究-以精神分裂病及躁鬱病為例》,行政院衛生署93年度科技研究計畫,計畫編號DOH93-TD-D-113-020-(2)。
高雅慧主持 (2000),《以ATC分類探討全民健保藥品之利用與分配》,行政院衛生署八十八年下半年及八十九年度委託研究計畫,計畫編號DOH89-NH-018。
葉玲玲、李玉春、楊銘欽、劉素愷，胡海國(1997) 《嚴重精神病患經濟成本之研究》,中華心理衛生3,1-15。
胡海國 (2002),“精神分裂症之社區流行病學”, 當代醫學, 29（9）：717-727。
陳大申 (2003),“臺灣地區精神疾病醫療利用分析”,長庚大學醫務管理研究所碩士論文。
張家銘 (2005),“精神分裂症、抗精神病藥物與糖尿病的關係-健保資料分析”,行政院國家科學委員會補助專題計畫成果研究報告。
張樂心 (2004),“不同醫院權屬別之經濟行為研究”,國立臺灣大學公共衛生學院衛生政策與管理研究所。
連賢明 (2006),“健保資料庫簡介”,經濟論文叢刊。
黃瑞媛 (2000),“服用非傳統抗精神病藥物之精神分裂症病患對藥物的態度及相關因素探討”,國立台灣大學護理所碩士論文。 |
